Immunomedics (NASDAQ:IMMU) is scheduled to be announcing its earnings results before the market opens on Thursday, May 9th. Analysts expect the company to announce earnings of ($0.34) per share for the quarter.
Immunomedics (NASDAQ:IMMU) last posted its quarterly earnings data on Monday, February 25th. The biopharmaceutical company reported ($0.50) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.34) by ($0.16). On average, analysts expect Immunomedics to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
Shares of NASDAQ IMMU traded down $0.15 on Friday, reaching $14.75. 39,108 shares of the company traded hands, compared to its average volume of 3,054,520. Immunomedics has a fifty-two week low of $11.55 and a fifty-two week high of $27.33. The company has a debt-to-equity ratio of 0.06, a current ratio of 13.45 and a quick ratio of 13.45. The company has a market cap of $2.83 billion, a P/E ratio of -14.34 and a beta of 1.97.
COPYRIGHT VIOLATION WARNING: “Immunomedics (IMMU) Set to Announce Quarterly Earnings on Thursday” was originally reported by Week Herald and is the sole property of of Week Herald. If you are viewing this article on another website, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The legal version of this article can be accessed at https://weekherald.com/2019/05/03/immunomedics-immu-set-to-announce-quarterly-earnings-on-thursday.html.
Immunomedics, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer. Its advanced antibody-drug conjugates are sacituzumab govitecan and labetuzumab govitecan, which are in advanced trials for various solid tumors and metastatic colorectal cancer, respectively.
Featured Article: What is a Derivative?
Receive News & Ratings for Immunomedics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics and related companies with MarketBeat.com's FREE daily email newsletter.